British genomics interpretation software vendor Congenica will help researchers analyze WGS and WES in search of a genetic cause for sudden unexpected death in epilepsy.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
Results from a small study suggest that blood biomarkers could be used to test for acute sleep loss and related problems such as drowsy driving.
With their strategic partnership, the bioinformatics firms seek to "break the biomarker bottleneck" that is holding back the potential of multi-omics research.
Fueled by an NIH SBIR grant, analytics firm Cytobank is building out its machine-learning algorithms and adding pipelines to support big-picture research.
Linguamatics' I2E natural language processing engine helps Sanofi match HLA alleles with multiple sclerosis and associated drug treatments.
The PMSC, which formally opened last week, offers mass spectrometry and sequencing resources to help customers develop robust and scalable workflows.
CytoReason's machine-learning algorithms extract information from multi-omic measurements to improve indication prioritization and highlight new treatment targets.
Six microRNAs appeared to be present at enhanced levels in cerebrospinal fluid from symptom-free individuals with characteristic Huntington disease gene expansions.
Vendors DNAnexus and Saphetor hope to create a seamless platform for genome-based biomarker discovery and interpretation.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.